Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late‐life dementia-Reference-Cited by-同舟云学术

Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late‐life dementia

Published:2006-10 Issue:4 Volume:2 Page:287-293
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Clark Christopher M.¹²³,Pratico Domenico⁴,Shaw Lesley M.⁵,Leight Susan⁵⁶,Xie Sharon X.²,Gu Amy⁵²,Lee Virginia M.-Y.⁵²⁶³,Trojanowski John Q.⁵²⁶³

Affiliation:

1. Department of NeurologyUniversity of PennsylvaniaPhiladelphiaPennsylvania

2. Alzheimer℉s Disease CenterUniversity of PennsylvaniaPhiladelphiaPennsylvania

3. Institute on AgingUniversity of PennsylvaniaPhiladelphiaPennsylvania

4. Department of MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvania

5. Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvania

6. Center for Neurodegenerative Disease ResearchUniversity of PennsylvaniaPhiladelphiaPennsylvania

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2006.05.2347

Reference27 articles.

1. M.S.Forman J.Farmer J.K.Johnson C.M.Clark S.E.Arnold H.B.Coslett et al.Frontotemporal dementia: Clinicopathological correlations. Ann Neurol.2006(In press)

2. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer℉s disease;Grossman M.;Ann Neurol,2005

3. Biological markers for therapeutic trials in Alzheimer℉s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer℉s disease;Frank R.A.;Neurobiol Aging,2003

4. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer℉s disease;Blennow K.;Mol Neurobiol,2001

5. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?;Clark C.M.;Arch Neurol,2003

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebrospinal Fluid Complement 4 Levels Were Associated with Alzheimer’s Disease Pathology and Cognition in Non-Demented Elderly;Journal of Alzheimer's Disease;2023-11-21

2. Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future;Journal of Pharmaceutical and Biomedical Analysis;2022-02

3. Proteomic analysis of plasma from a Tau transgenic mouse;International Journal of Developmental Neuroscience;2012-03

4. Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors;European Journal of Medicinal Chemistry;2011-08

5. Biomarkers for Cognitive Impairment in Parkinson Disease;Brain Pathology;2010-05